The traditional view of Alzheimer's disease as primarily a protein misfolding disorder is giving way to a more complex understanding that places immune dysfunction at the disease's core. This shift has profound implications for how we approach prevention and treatment of the most common form of dementia affecting millions worldwide.
Advanced single-cell sequencing techniques have revealed that brain immune cells—microglia and astrocytes—exist in distinct subpopulations with specialized inflammatory programs. Key molecular pathways including TREM2–APOE, NF-κB, JAK/STAT, and NLRP3 inflammasome signaling orchestrate chronic inflammation that both impairs the brain's ability to clear amyloid-beta plaques and accelerates toxic tau protein accumulation. The complement system's C1q–C3 axis simultaneously triggers excessive removal of healthy synapses, contributing to cognitive decline.
Perhaps most significantly, this inflammatory cascade extends far beyond the brain. Peripheral immune cells breach the compromised blood-brain barrier, while gut microbiome disruption sends inflammatory signals through the gut-brain axis, creating a self-perpetuating cycle of neuroinflammation. This represents a paradigm shift from viewing Alzheimer's as an isolated brain disorder to understanding it as a systemic inflammatory condition.
The clinical implications are substantial. Biomarkers like GFAP, sTREM2, and YKL-40 now allow real-time monitoring of brain inflammation, potentially enabling earlier intervention. However, the complexity of these interconnected immune networks presents both opportunity and challenge—while offering multiple therapeutic targets, it also suggests that successful treatments may need to address systemic rather than just brain-specific inflammation.